Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 8 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
The Rockefeller University manages a portfolio with 11 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 8 distinct art units, which suggests a broad range of biological and pharmaceutical research topics are being patented. The prosecution involves 11 distinct examiners, meaning that every pending office action is being handled by a different individual at the USPTO.
MARTIN, PAUL C is identified as the busiest examiner, though he only has 1 pending action. This highlights the high degree of fragmentation in the portfolio, as no examiner is responsible for multiple active matters. With the workload spread across 8 distinct art units, the university must navigate a wide variety of examiner styles and art unit cultures. This decentralized prosecution environment requires a versatile approach to managing the current workload.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (36%) |
| §112 only | 3 (27%) |
| Double-patenting only | 1 (9%) |
| Multi-statute (no §101) | 3 (27%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARTIN, PAUL C | 1 | 41.8% | +21.6% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +35.1% |
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
| VARADARAJ, ARCHANA | 1 | 80.0% | +33.3% |
| PARKIN, JEFFREY S | 1 | 63.7% | +21.7% |
| LU, CHENG | 1 | 54.1% | +64.1% |
| GUSSOW, ANNE | 1 | 57.9% | +43.8% |
| GOLDBERG, JEANINE ANNE | 1 | 45.8% | +40.8% |
| DEBERRY, REGINA M | 1 | 50.1% | +30.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18255043 | COMPOSITIONS AND METHODS FOR RAPID PRODUCTION OF VERSATILE SINGLE DOMAIN ANTIBODY REPERTOIRES | LU, CHENG | 17d overdue |
| 18902455 | COMPOSITIONS AND METHODS FOR PRODUCING HAIR FOLLICLE STEM CELLS | MARTIN, PAUL C | — |
| 18558066 | NEUTRALIZING ANTI- SARS-COV-2 ANTIBODIES AND METHODS OF USE THEREOF | AEDER, SEAN E | — |
| 18557654 | MACOLACINS AND METHODS OF USE THEREOF | VARADARAJ, ARCHANA | — |
| 18340008 | HIV VACCINE IMMUNOGENS | PARKIN, JEFFREY S | — |
| 17928424 | METHOD AND SYSTEM FOR RNA ISOLATION FROM SELF-COLLECTED AND SMALL VOLUME SAMPLES | GUSSOW, ANNE | — |
| 17994090 | MARKERS AND CELLULAR ANTECEDENTS OF RHEUMATOID ARTHRITIS FLARES | GOLDBERG, JEANINE ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18255043 | COMPOSITIONS AND METHODS FOR RAPID PRODUCTION OF VERSATILE SINGLE DOMAIN ANTIBODY REPERTOIRES | LU, CHENG | 17d overdue |
| 18902455 | COMPOSITIONS AND METHODS FOR PRODUCING HAIR FOLLICLE STEM CELLS | MARTIN, PAUL C | — |
| 18294336 | PYRROLOPYRIDINE-3- AND 4-CARBOXAMIDE COMPOSITIONS AND METHODS FOR CELLULAR PROLIFERATION | PECKHAM, RICHARD GRANT | — |
| 18558066 | NEUTRALIZING ANTI- SARS-COV-2 ANTIBODIES AND METHODS OF USE THEREOF | AEDER, SEAN E | — |
| 18557654 | MACOLACINS AND METHODS OF USE THEREOF | VARADARAJ, ARCHANA | — |
| 18340008 | HIV VACCINE IMMUNOGENS | PARKIN, JEFFREY S | — |
| 17928424 | METHOD AND SYSTEM FOR RNA ISOLATION FROM SELF-COLLECTED AND SMALL VOLUME SAMPLES | GUSSOW, ANNE | — |
| 17994090 | MARKERS AND CELLULAR ANTECEDENTS OF RHEUMATOID ARTHRITIS FLARES | GOLDBERG, JEANINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1642 | 2 |
| 1627 | 1 |
| 1653 | 1 |
| 1671 | 1 |
| 1683 | 1 |
| 1682 | 1 |
| 1647 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18902455 | COMPOSITIONS AND METHODS FOR PRODUCING HAIR FOLLICLE STEM CELLS | MARTIN, PAUL C | — | §102§112 | Non-Final OA | — | Pending | Sep 30, 2024 |
| 18833645 | BROADLY NEUTRALIZING ANTI-SARS-COV-2 ANTIBODIES TARGETING THE N-TERMINAL DOMAIN OF THE SPIKE PROTEIN AND METHODS OF USE THEREOF | ALAM, DANYAL HASSAN | — | §112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18294336 | PYRROLOPYRIDINE-3- AND 4-CARBOXAMIDE COMPOSITIONS AND METHODS FOR CELLULAR PROLIFERATION | PECKHAM, RICHARD GRANT | 1627 | §112 | Non-Final OA | — | Pending | Feb 01, 2024 |
| 18558066 | NEUTRALIZING ANTI- SARS-COV-2 ANTIBODIES AND METHODS OF USE THEREOF | AEDER, SEAN E | 1642 | §101§112 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18557654 | MACOLACINS AND METHODS OF USE THEREOF | VARADARAJ, ARCHANA | 1653 | §101§102§103 | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18340008 | HIV VACCINE IMMUNOGENS | PARKIN, JEFFREY S | 1671 | §102§112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18255043 | COMPOSITIONS AND METHODS FOR RAPID PRODUCTION OF VERSATILE SINGLE DOMAIN ANTIBODY REPERTOIRES | LU, CHENG | 1642 | §101§102§103 | Non-Final OA | 17d overdue | Pending | May 30, 2023 |
| 17928424 | METHOD AND SYSTEM FOR RNA ISOLATION FROM SELF-COLLECTED AND SMALL VOLUME SAMPLES | GUSSOW, ANNE | 1683 | §102§103§112 | Final Rejection | — | Pending | Nov 29, 2022 |
| 17994090 | MARKERS AND CELLULAR ANTECEDENTS OF RHEUMATOID ARTHRITIS FLARES | GOLDBERG, JEANINE ANNE | 1682 | §101§102§112DPOther | Non-Final OA | — | Pending | Nov 25, 2022 |
| 17794724 | PHASE SEPARATION SENSORS AND USES THEREOF | DEBERRY, REGINA M | 1647 | §112 | Final Rejection | — | Pending | Jul 22, 2022 |
| 17503928 | CRISPR-CAS COMPONENT SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION | LEITH, NANCY J | 1636 | DP | Non-Final OA | — | Pending | Oct 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial